Filter by: patients
Home > Community Treatment Reports and Side Effects > Dalfampridine (4-AP extended release) Treatment Report
What is Dalfampridine (4-AP extended release)?

Dalfampridine, is an extended release formulation of 4-aminopyridine or 4-AP. It is a potassium channel blocker that is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). Dalfampridine was previously called Fampridine-SR during clinical trials.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 594 130 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Improve mobility 227 117 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Walking problems 137 63 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Improve flexibility/strength 33 11 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_cant_tell
Fatigue 29 11 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Imbalance when walking 25 16 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell

See all 712 patients currently taking Dalfampridine (4-AP extended release)

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 21
Moderate
 32
Mild
 73
None
 166

Commonly reported side effects, conditions, and hospitalizations associated with Dalfampridine (4-AP extended release)

Insomnia 18
Dizziness 16
Nausea 8
Constipation 7
Headaches 7
Dizziness and feeling faint 6
See all 83 reported side effects ▼ See top 6 reported side effects ▲

Reported Dosages

Frequently reported dosages based on patients currently taking Dalfampridine (4-AP extended release). See all 45 dosages ►

  1 mg daily 2 other daily 2 mg daily 5 mg daily 10 mg daily 15 mg daily 20 mg daily 30 mg daily 40 mg daily 60 mg daily
  11 Number of Patients: 11 16 Number of Patients: 16 24 Number of Patients: 24 10 Number of Patients: 10 169 Number of Patients: 169 14 Number of Patients: 14 376 Number of Patients: 376 26 Number of Patients: 26 17 Number of Patients: 17 7 Number of Patients: 7  

Reported Stop Reasons

Why Patients Stopped Taking Dalfampridine (4-AP extended release) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 104   Did not seem to work: 46%
Side effects too severe 61   Side effects too severe: 27%
Other 44   Other: 20%
Doctor's advice 30   Doctor's advice: 13%
Expense 25   Expense: 11%
Change in health plan coverage 9   Change in health plan coverage: 4%
Course of treatment ended 8   Course of treatment ended: 4%
Personal research 6   Personal research: 3%
Not indicated 5   Not indicated: 2%

See all 214 patients who’ve stopped taking Dalfampridine (4-AP extended release)

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Dalfampridine (4-AP extended release)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Stopped Taking Dalfampridine (4-AP extended release)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Dalfampridine (4-AP extended release)

Always
 232 79%
Usually
 42 14%
Sometimes
 5 2%
Never
 13 4%

Burden

Difficulty being on treatment

Burden of Dalfampridine (4-AP extended release)

Very
 6 2%
Somewhat
 14 5%
A little
 39 13%
Not at all
 233 80%

Cost

Paid out of pocket

Cost of Dalfampridine (4-AP extended release)

$200+
 12 5%
$100-199
 13 5%
$50-99
 53 22%
$25-49
 88 36%
< $25
 77 32%

Report created on May 28, 2012.